Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial (2020)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1177/1740774520943846
- Subjects: ADULTOS; ANTICOAGULANTES; TROMBOSE; RESULTADO DE TRATAMENTO; PANDEMIAS; COVID-19
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Clinical trials
- ISSN: 1740-7745
- Volume/Número/Paginação/Ano: v. 17, n. 5, p. 491-500, 2020
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
HOUSTON, Brett L et al. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical trials, v. 17, n. 5, p. 491-500, 2020Tradução . . Disponível em: https://doi.org/10.1177/1740774520943846. Acesso em: 04 mar. 2026. -
APA
Houston, B. L., Lawler, P. R., Goligher, E. C., Farkouh, M. E., Bradbury, C., Carrier, M., et al. (2020). Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical trials, 17( 5), 491-500. doi:10.1177/1740774520943846 -
NLM
Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M, Dzavik V, Fergusson DA, Fowler RA, Nicolau JC. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial [Internet]. Clinical trials. 2020 ; 17( 5): 491-500.[citado 2026 mar. 04 ] Available from: https://doi.org/10.1177/1740774520943846 -
Vancouver
Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M, Dzavik V, Fergusson DA, Fowler RA, Nicolau JC. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial [Internet]. Clinical trials. 2020 ; 17( 5): 491-500.[citado 2026 mar. 04 ] Available from: https://doi.org/10.1177/1740774520943846 - Sex difference in patients with ischemic heart failure undergoing surgical revascularization results from the STICH trial (Surgical Treatment for Ischemic Heart Failure)
- Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial
- Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Coronary Stent Registry
- Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial
- Aneurisma Verdadeiro Gigante e Calcificado do Ventrículo Esquerdo: como Proceder?
- Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
- Comparison between two different local hemostatic methods for dental extractions in patients on dual antiplatelet therapy: a within-person, single-blind, randomized study
- Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B
- Predictors of subclinical carotid atherosclerosis in middle-aged women
Informações sobre o DOI: 10.1177/1740774520943846 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
